Aaron M Rulseh
Overview
Explore the profile of Aaron M Rulseh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akbari H, Bakas S, Sako C, Kazerooni A, Villanueva-Meyer J, Garcia J, et al.
Neuro Oncol
. 2024 Dec;
PMID: 39665363
Background: Glioblastoma is the most aggressive adult primary brain cancer, characterized by significant heterogeneity, posing challenges for patient management, treatment planning, and clinical trial stratification. Methods: We developed a highly...
2.
Vymazal J, Rulseh A
Insights Imaging
. 2024 Jul;
15(1):179.
PMID: 39060665
Gadolinium-based contrast agents (GBCA) were introduced with high expectations for favorable efficacy, low nephrotoxicity, and minimal allergic-like reactions. Nephrogenic systemic fibrosis and proven gadolinium retention in the body including the...
3.
Vymazal J, Ryznarova Z, Rulseh A
Insights Imaging
. 2024 Mar;
15(1):73.
PMID: 38483648
Objectives: Accurate detection of metastatic brain lesions (MBL) is critical due to advances in radiosurgery. We compared the results of three readers in detecting MBL using T1-weighted 2D spin echo...
4.
Ballo M, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh A
J Neurooncol
. 2023 Jul;
164(1):1-9.
PMID: 37493865
Purpose: Tumor Treating Fields (TTFields) therapy, an electric field-based cancer treatment, became FDA-approved for patients with newly diagnosed glioblastoma (GBM) in 2015 based on the randomized controlled EF-14 study. Subsequent...
5.
Vymazal J, Kazda T, Novak T, Slanina P, Sroubek J, Klener J, et al.
Front Oncol
. 2023 Feb;
12:1014455.
PMID: 36741707
Introduction: The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150-300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are...
6.
Neburkova J, Rulseh A, Chang S, Raabova H, Vejpravova J, Dracinsky M, et al.
Nanoscale Adv
. 2022 Sep;
2(12):5567-5571.
PMID: 36133872
Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd-ferritin nanoparticles at (sub)nanomolar concentrations of...
7.
Vymazal J, Kramska L, Brozova H, Ruzicka E, Rulseh A
J Magn Reson Imaging
. 2019 Oct;
51(6):1912-1913.
PMID: 31664740
No abstract available.
8.
Syka M, Keller J, Klempir J, Rulseh A, Roth J, Jech R, et al.
PLoS One
. 2015 Mar;
10(3):e0118907.
PMID: 25781024
Huntington's disease (HD) is an inherited neurodegenerative disorder with progressive impairment of motor, behavioral and cognitive functions. The clinical features of HD are closely related to the degeneration of the...
9.
Keller J, Rulseh A, Komarek A, Latnerova I, Rusina R, Brozova H, et al.
PLoS One
. 2013 Aug;
8(8):e71431.
PMID: 23990954
Fractional anisotropy (FA) is the most commonly used quantitative measure of diffusion in the brain. Changes in FA have been reported in many neurological disorders, but the implementation of diffusion...
10.
Rulseh A, Keller J, Tintera J, Kozisek M, Vymazal J
J Magn Reson Imaging
. 2013 Feb;
38(5):1103-10.
PMID: 23440865
Purpose: To characterize the relationship between superparamagnetic ferritin-bound iron and diffusion tensor scalars in vitro, and validate the results in vivo. Materials And Methods: The in vitro model consisted of...